SCHEMBL3982737

SCHEMBL3982737

COc1ccc(S(=O)(=O)Nc2ccc3cc[nH]c3c2C(=O)O)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.53
PTPRC P08575 1/20 0.50
PTPN2 P17706 1/20 0.50
PTPN1 P18031 1/20 0.50
PTPRB P23467 1/20 0.50
PTPRE P23469 1/20 0.50
PTPN6 P29350 1/20 0.50
KEAP1 Q14145 3/20 0.49
NFE2L2 Q16236 2/20 0.49
SQSTM1 Q13501 1/20 0.49
TUBB4A P04350 1/20 0.47
TUBB P07437 1/20 0.47
TUBA3C P0DPH7 1/20 0.47
TUBA1B P68363 1/20 0.47
TUBA4A P68366 1/20 0.47
TUBB4B P68371 1/20 0.47
TUBB3 Q13509 1/20 0.47
TUBB2A Q13885 1/20 0.47
TUBB8 Q3ZCM7 1/20 0.47
TUBA3E Q6PEY2 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3982706 0.87 PTPRC (0.53) ESR1PTPRCPTPN2PTPN1PTPRB
SCHEMBL3982699 0.85 METAP2 (0.63) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3985610 0.84 PTPRC (0.53) ESR1PTPRCPTPN2PTPN1PTPRB
SCHEMBL3988437 0.84 METAP2 (0.62) ESR1PTPRCPTPN2PTPN1PTPRB
SCHEMBL3988030 0.83 PTPRC (0.45) ESR1PTPRCPTPN2PTPN1PTPRB
SCHEMBL2403697 0.79 TUBB4A (0.61) ESR1KEAP1NFE2L2SQSTM1TUBB4A
SCHEMBL3984259 0.79 METAP2 (0.76) KEAP1NFE2L2SQSTM1ALDH1A1METAP2
SCHEMBL3982247 0.78 PTPRC (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL3982513 0.76 METAP2 (0.49) PTPRCPTPN2PTPN1PTPRBPTPRE
SCHEMBL22825226 0.75 METAP2 (0.62) KEAP1NFE2L2SQSTM1CYP2C9ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7491718-B2 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES (US) 2009-02-17 US disclosed
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity ABBVIE INC. 2004-08-26 US disclosed
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity ABBOTT LABORATORIES 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167128-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP ESR1 4654/4885PTPRC 2454/4885PTPN2 964/4885
US-20040157836-A1 Sulfonamides having antiangiogenic and anticancer activity METAP2, METAP1, DNPEP ESR1 4654/4885PTPRC 2454/4885PTPN2 964/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.